Nirmatrelvir–Ritonavir Reduced Mortality in Hospitalized Patients with COVID-19 During the Omicron Outbreak: Real-World Evidence from Beijing
Yi Zhang,Xinrui Wang,Chong Huang,Hui Yang,Chunguo Jiang,Xiaojia Yu,Jun Hong,Yi Zhang,Yushu Wang,Rui Zhao,Zhuoling An,Zhaohui Tong
DOI: https://doi.org/10.2147/idr.s445826
2024-04-09
Infection and Drug Resistance
Abstract:Yi Zhang, 1, &ast Xinrui Wang, 1, &ast Chong Huang, 2 Hui Yang, 1 Chunguo Jiang, 3 Xiaojia Yu, 1 Jun Hong, 2 Yi Zhang, 1 Yushu Wang, 1 Rui Zhao, 1 Zhuoling An, 1 Zhaohui Tong 3 1 Department of Pharmacy, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, People's Republic of China; 2 School of Pharmaceutical Sciences, Capital Medical University, Beijing, People's Republic of China; 3 Department of Respiratory and Critical Care Medicine, Beijing Institute of Respiratory Medicine, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, People's Republic of China &astThese authors contributed equally to this work Correspondence: Zhuoling An, Department of Pharmacy, Beijing Chao-Yang Hospital, Capital Medical University, 8 Gongren Tiyuchang Nanlu, Chaoyang District, Beijing, 100020, People's Republic of China, Tel +00-86-010-85231362, Email Zhaohui Tong, Department of Respiratory and Critical Care Medicine, Beijing Institute of Respiratory Medicine, Beijing Chao-Yang Hospital, Capital Medical University, 8 Gongren Tiyuchang Nanlu, Chaoyang District, Beijing, 100020, People's Republic of China, Tel +00-86-010-85231464, Email Objective: The efficacy of nirmatrelvir–ritonavir for hospitalized patients with COVID-19 has not been fully established. Methods: We conducted a retrospective analysis of hospitalized COVID– 19 patients with high risk for disease progression at Beijing Chaoyang Hospital from October 15, 2022, to March 31, 2023. Patients ≥ 18 years old who were hospitalized with COVID-19 within 5 days of symptom onset were included. Baseline data were obtained from the routine electronic health record database of the hospital information system. Outcomes were monitored at 28 days via electronic medical record reviews or telephone interviews. Results: We identified 1120 patients hospitalized with COVID-19 during the study period. After exclusions, 167 nirmatrelvir–ritonavir users and 132 controls were included. 28-day all-cause mortality rate was 12.0% (20/167) in the nirmatrelvir–ritonavir group, versus 22.7% (30/132) in the control group (unadjusted log-rank p = 0.010; HR = 0.49, 95% confidence interval [CI] = 0.28– 0.86, IPTW-adjusted HR = 0.58, 95% CI = 0.40– 0.86). The 28-day disease progression rates did not differ between the two groups (unadjusted HR = 0.59, 95% CI = 0.34– 1.02, IPTW-adjusted HR = 0.73, 95% CI = 0.50– 1.06). Nirmatrelvir–ritonavir significantly reduced all-cause mortality and disease progression within 28 days among patients aged ≥ 65 years without ≥ 2 vaccine doses. Conclusion: We found significantly reduced all-cause mortality in the nirmatrelvir–ritonavir group, particularly in elderly patients who were incompletely vaccinated. Future randomized controlled studies are needed to validate our findings. Keywords: nirmatrelvir–ritonavir, COVID-19, hospitalized In December 2022, China experienced a surge of infections by the SARS-CoV-2 Omicron variant, resulting in a substantial strain on the healthcare system. 1,2 In response, the medical community has actively sought to identify effective treatments to mitigate the morbidity and mortality of this infection. Nirmatrelvir–ritonavir (Paxlovid), an oral antiviral drug, has displayed significant benefits in non-hospitalized patients with COVID-19. 3 Emergency use authorization was granted for nirmatrelvir–ritonavir in the treatment of non-hospitalized patients with COVID-19 by the US Food and Drug Administration in December 2021. 4 However, guidelines from the World Health Organization and US National Institutes of Health currently recommend nirmatrelvir–ritonavir only for non-hospitalized patients at high risk of hospitalization. 5,6 The efficacy of nirmatrelvir–ritonavir for hospitalized patients with COVID-19, who might experience rapid disease progression and require more supportive care, has not been established. Previous clinical evidence indicated favorable outcomes for nirmatrelvir–ritonavir in hospitalized patients with COVID-19, including reductions in all-cause mortality, disease progression, 7,8 and the need for oxygen therapy in patients without supplemental oxygen. 8 However, these studies provided limited information regarding oxygen support, making it challenging to ascertain the drug's efficacy in different disease stages. Furthermore, the potential benefits of nirmatrelvir–ritonavir in specific populations warrant further exploration. Previous studies found that older non-hospitalized adults with COVID-19 might derive more significant benefits from nirmatrelvir–riton -Abstract Truncated-
pharmacology & pharmacy,infectious diseases